Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
111In-PSMA-I&T
- Development stage
- Unknown
- Lead developer
- Technical University of Munich
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
111In-PSMA-I&T is a radiopharmaceutical designed for the targeted detection and intraoperative localization of prostate cancer metastases. It consists of a peptidomimetic urea-based ligand (PSMA-I&T) that binds with high affinity to the extracellular domain of the prostate-specific membrane antigen (PSMA), which is frequently overexpressed in prostate cancer cells. This ligand is conjugated via a DOTAGA chelator to Indium-111, a gamma-emitting radioisotope. The primary clinical utility of 111In-PSMA-I&T is in radioguided surgery (RGS), where it enables surgeons to use a gamma probe to identify and resect small, otherwise occult lymph node metastases and soft-tissue lesions. Additionally, it can be used for preoperative SPECT imaging to map disease spread.
- Other names
- indium-111 PSMA-I&T111In-PSMA-I and T111In-PSMA imaging and therapy
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 111In-PSMA-I&T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 111In-PSMA-I&T.